SCHEMBL5380381

SCHEMBL5380381

Cc1ccc(S(=O)(=O)Nc2ccc(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cc2)cc1C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.61
RXRA P19793 2/20 0.53
RXRB P28702 2/20 0.53
KDM1A O60341 3/20 0.52
CYP2D6 P10635 2/20 0.52
PSEN1 P49768 2/20 0.52
PSEN2 P49810 2/20 0.52
APH1B Q8WW43 2/20 0.52
NCSTN Q92542 2/20 0.52
APH1A Q96BI3 2/20 0.52
PSENEN Q9NZ42 2/20 0.52
ACLY P53396 3/20 0.49
HSD17B2 P37059 1/20 0.48
PLAU P00749 1/20 0.47
PLAT P00750 1/20 0.47
CYP3A4 P08684 1/20 0.47
BRD4 O60885 1/20 0.47
IDH1 O75874 1/20 0.46
RXRG P48443 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5373250 0.93 POLB (0.63) POLBKDM1AACLYHSD17B2BRD4
SCHEMBL5382236 0.90 ACLY (0.61) POLBKDM1AACLYHSD17B2PLAU
SCHEMBL5372103 0.89 POLB (0.53) POLBCYP2D6PSEN1PSEN2APH1B
SCHEMBL5368419 0.88 POLB (0.66) POLBKDM1AACLYHSD17B2BRD4
SCHEMBL5378765 0.85 POLB (0.65) POLBHSD17B2CYP3A4IDH1SMN1; SMN2
SCHEMBL5501882 0.84 POLB (0.70) POLBSMN1; SMN2MEN1MAPK1KMT2A
SCHEMBL5320408 0.83 POLB (0.69) POLBIDH1SMN1; SMN2
SCHEMBL5373144 0.82 POLB (0.53) POLBHSD17B2BRD4SMN1; SMN2
SCHEMBL5371871 0.82 MEN1 (0.57) POLBKDM1ACYP2D6PSEN1PSEN2
SCHEMBL5386663 0.81 POLB (0.57) POLBACLYHSD17B2SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 EP disclosed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US disclosed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US disclosed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD POLB 1807/4885RXRA 44/4885RXRB 66/4885
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARG, PPARA, PPARD POLB 2006/4885RXRA 69/4885RXRB 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.